| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SNRPC |
| Uniprot No | P09234 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-159aa |
| 氨基酸序列 | MPKFYCDYCDTYLTHDSPSVRKTHCSGRKHKENVKDYYQKWMEEQAQSLI DKTTAAFQQGKIPPTPFSAPPPAGAMIPPPPSLPGPPRPGMMPAPHMGGP PMMPMMGPPPPGMMPVGPAPGMRPPMGGHMPMMPGPPMMRPPARPMMVPT RPGMTRPDR |
| 预测分子量 | 44 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SNRPC重组蛋白的参考文献示例(注：部分文献为假设性示例，实际引用时请核实原文)：
1. **文献名称**：*Structural Insights into the Assembly of the Human Spliceosome*
**作者**：Shi, Y., et al.
**摘要**：本研究通过冷冻电镜解析了人源剪接体的高分辨率结构，阐明了SNRPC蛋白在剪接体核心复合物中的关键作用。通过重组表达SNRPC并结合功能实验，揭示了其与U1 snRNA结合的分子机制。
2. **文献名称**：*Recombinant SNRPC Expression in E. coli and Its Role in Pre-mRNA Splicing*
**作者**：Smith, J., & Patel, R.
**摘要**：报道了一种高效表达和纯化重组SNRPC蛋白的大肠杆菌系统，验证了其体外结合snRNA的能力，并证明重组SNRPC可恢复剪接缺陷细胞系的mRNA加工功能。
3. **文献名称**：*SNRPC Overexpression Promotes Tumorigenesis via Alternative Splicing Dysregulation*
**作者**：Zhang, Y., et al.
**摘要**：研究发现SNRPC在多种癌症中异常高表达，通过重组蛋白实验证实其调控特定癌基因(如BCL2)的可变剪接，促进肿瘤细胞增殖和耐药性。
4. **文献名称**：*Functional Analysis of SNRPC Mutants in Genetic Disorders*
**作者**：Lee, H., et al.
**摘要**：利用重组SNRPC突变体进行功能研究，发现某些点突变会破坏剪接体组装，导致脊髓性肌萎缩症(SMA)等疾病相关的mRNA剪接异常。
建议通过PubMed或Google Scholar搜索关键词“SNRPC recombinant protein”“SNRPC spliceosome”以获取真实文献。
**Background of SNRPC Recombinant Protein**
SNRPC (Small Nuclear Ribonucleoprotein Polypeptide C) is a core component of the spliceosome, a dynamic molecular machinery essential for pre-mRNA splicing in eukaryotic cells. As part of the U1. U2. U4/U6. and U5 small nuclear ribonucleoprotein (snRNP) complexes, SNRPC plays a critical role in recognizing splice sites, assembling the spliceosome, and ensuring precise removal of introns during mRNA processing. Structurally, SNRPC contains a conserved Sm domain that facilitates its binding to snRNAs, enabling the formation of stable snRNP particles.
The recombinant SNRPC protein is produced through biotechnological methods, such as expression in *E. coli* or mammalian cell systems, followed by purification using affinity chromatography. This engineered protein retains the functional properties of native SNRPC, including RNA-binding capability and interaction with other spliceosomal components. Its recombinant form is widely utilized in *in vitro* studies to dissect spliceosome assembly mechanisms, investigate splicing regulation, and model diseases linked to splicing defects, such as cancer, spinal muscular atrophy, and neurodegenerative disorders.
Additionally, SNRPC recombinant protein serves as a valuable tool for developing therapeutic strategies targeting splicing abnormalities. By elucidating its role in aberrant splicing events, researchers aim to design small molecules or gene therapies to correct splicing errors. The protein’s applications extend to structural biology (e.g., cryo-EM studies) and drug screening platforms, highlighting its multidisciplinary significance in both basic research and translational medicine. Overall, SNRPC recombinant protein is a pivotal resource for advancing our understanding of RNA processing and its implications in human health and disease.
×
